Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Healthcare stock trading at $55.22 (as of 2026-06-18), with a market capitalization of $3.99B and a trailing P/E of 53.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company engaged in discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating conditions and unmet medical needs. Its pipeline includes ARCALYST for recurrent pericarditis, mavrilimumab for giant cell arteritis, vixarelimab for prurigo nodularis, and KPL-404 for immune-related indications.